Demant A/S

BATS-CHIXE:DEMANC Stock Report

Market Cap: DKK 57.6b

Demant Valuation

Is DEMANC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DEMANC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DEMANC (DKK268.1) is trading below our estimate of fair value (DKK483.18)

Significantly Below Fair Value: DEMANC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DEMANC?

Key metric: As DEMANC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DEMANC. This is calculated by dividing DEMANC's market cap by their current earnings.
What is DEMANC's PE Ratio?
PE Ratio22.7x
EarningsDKK 2.54b
Market CapDKK 57.65b

Price to Earnings Ratio vs Peers

How does DEMANC's PE Ratio compare to its peers?

The above table shows the PE ratio for DEMANC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.9x
SN. Smith & Nephew
35.3x22.5%UK£8.6b
NIOX NIOX Group
23.7x17.1%UK£260.3m
CTEC ConvaTec Group
40.4x20.5%UK£4.9b
EKF EKF Diagnostics Holdings
24.4xn/aUK£113.4m
DEMANC Demant
22.7x12.4%DKK 57.6b

Price-To-Earnings vs Peers: DEMANC is good value based on its Price-To-Earnings Ratio (22.7x) compared to the peer average (30.9x).

Price to Earnings Ratio vs Industry

How does DEMANC's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DEMANC is good value based on its Price-To-Earnings Ratio (22.7x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is DEMANC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DEMANC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate DEMANC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DEMANC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
DKK 297.47
0%
10.0%DKK 350.00DKK 245.00n/a17
Nov ’25DKK 258.80
DKK 302.41
+16.9%
10.4%DKK 360.00DKK 250.00n/a17
Oct ’25DKK 269.60
DKK 301.31
+11.8%
11.1%DKK 370.00DKK 250.00n/a16
Sep ’25DKK 285.90
DKK 303.81
+6.3%
11.6%DKK 370.00DKK 230.00n/a16
Aug ’25DKK 251.90
DKK 314.94
+25.0%
13.9%DKK 381.00DKK 230.00n/a16
Jul ’25n/a
DKK 336.69
0%
14.1%DKK 400.00DKK 268.00n/a16
Jun ’25DKK 328.10
DKK 337.31
+2.8%
14.3%DKK 400.00DKK 268.00n/a16
May ’25n/a
DKK 334.75
0%
15.5%DKK 400.00DKK 240.00n/a16
Apr ’25DKK 343.40
DKK 339.47
-1.1%
15.8%DKK 405.00DKK 240.00n/a17
Mar ’25n/a
DKK 336.53
0%
15.1%DKK 400.00DKK 240.00n/a17
Feb ’25n/a
DKK 298.71
0%
13.5%DKK 355.00DKK 235.00n/a17
Jan ’25n/a
DKK 288.71
0%
15.1%DKK 350.00DKK 185.00n/a17
Dec ’24n/a
DKK 286.76
0%
13.4%DKK 335.00DKK 185.00n/a17
Nov ’24n/a
DKK 287.69
0%
15.4%DKK 340.00DKK 185.00DKK 258.8016
Oct ’24n/a
DKK 286.47
0%
15.8%DKK 340.00DKK 185.00DKK 269.6015
Sep ’24DKK 292.95
DKK 285.94
-2.4%
15.4%DKK 340.00DKK 185.00DKK 285.9016
Aug ’24DKK 280.10
DKK 264.27
-5.7%
19.1%DKK 330.00DKK 180.00DKK 251.9015
Jul ’24DKK 289.45
DKK 256.60
-11.3%
20.2%DKK 330.00DKK 180.00n/a15
Jun ’24n/a
DKK 252.13
0%
20.9%DKK 330.00DKK 180.00DKK 328.1015
May ’24DKK 289.20
DKK 230.79
-20.2%
19.4%DKK 330.00DKK 180.00n/a14
Apr ’24n/a
DKK 222.00
0%
13.2%DKK 275.00DKK 180.00DKK 343.4013
Mar ’24DKK 213.00
DKK 218.00
+2.3%
14.8%DKK 275.00DKK 180.00n/a14
Feb ’24DKK 194.15
DKK 206.50
+6.4%
13.7%DKK 254.00DKK 170.00n/a14
Jan ’24DKK 188.95
DKK 215.23
+13.9%
16.7%DKK 285.00DKK 165.00n/a13
Dec ’23DKK 202.70
DKK 215.25
+6.2%
17.2%DKK 285.00DKK 165.00n/a12
Nov ’23n/a
DKK 249.08
0%
19.9%DKK 330.00DKK 176.00n/a12

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Guerbet

€341.1m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€27.00

7D

-9.8%

1Y

50.2%

Fagron

€1.4b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€17.98

7D

-6.5%

1Y

4.8%

Axogen

US$556.3m

Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.

0HKD

US$12.64

7D

-7.5%

1Y

108.9%